Michael Isaacman
![mike mike](https://www.elabnyc.com/wp-content/uploads/2018/05/mike.jpg)
Nanometics LLC
Affiliations
New York University
Technologies
Therapeutic
Indication
Basic Research
Clinical Research
Clinical Trials
Drug Discovery
Oncology
Orphan Diseases
Website
nanometicslab.comWe are developing an enzyme inhibitor with pico-‐molar binding affinity and minimal toxicity as a once daily, oral therapeutic for the treatment of triple-‐negative breast cancer.